1 sought to demonstrate the noninferiority of XELOX to FOLFOX-4 as second-line therapy ... counterparts—increased gastrointestinal adverse effects were observed, but less neurosensory toxicity.

Because FOLFOX and FOLFIRI are equally effective on the overall survival front, the decision between them comes down to a balance between patient comorbidities and side effect profiles.